Percheron Therapeutics Limited

Percheron Therapeutics Limited is a biotechnology company specializing in the research and development of novel antisense pharmaceuticals aimed at treating cancer and rare diseases. Headquartered in Melbourne, Australia, and established in 2000, the company has positioned itself at the forefront of RNA-targeted therapeutics, with a particular focus on areas of high unmet medical need. Its pipeline features prominent candidates such as ATL1102, an antisense inhibitor of CD49d, which is undergoing Phase II clinical trials for indications including Duchenne Muscular Dystrophy, multiple sclerosis, limb girdle muscular dystrophy, asthma, and other inflammatory disorders. Additionally, Percheron is developing advanced biologics, including recombinant antibodies designed to modulate immune pathways related to cancer progression. The company’s activities underscore its central role in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, by contributing innovative treatment options for both common and rare conditions. Through its sustained investment in therapeutic innovation and clinical development, Percheron Therapeutics Limited holds significance as part of Australia’s growing life sciences market.